Baidu
map

复杂冠脉介入术后,长期单用替格瑞洛优于标准双联抗血小板治疗

2019-05-31 朱朱 中国循环杂志

在近日召开的EuroPCR会议上,GLOBAL LEADERS研究的最新事后分析结果表明,对于复杂冠脉介入治疗(PCI)术后患者,与标准抗血小板治疗策略(1年双联抗血小板治疗+1年阿司匹林)相比,长期单用替格瑞洛策略(1个月双联抗血小板治疗后单用替格瑞洛)可能更好。

在近日召开的EuroPCR会议上,GLOBAL LEADERS研究的最新事后分析结果表明,对于复杂冠脉介入治疗(PCI)术后患者,与标准抗血小板治疗策略(1年双联抗血小板治疗+1年阿司匹林)相比,长期单用替格瑞洛策略(1个月双联抗血小板治疗后单用替格瑞洛)可能更好。

这与GLOBAL LEADERS研究的主分析结果并不一致,后者显示,在因急性冠脉综合征或稳定性冠心病置入冠脉支架的患者中,长期单用替格瑞洛策略在减少2年主要不良事件(全因死亡或新发Q波心肌梗死)上并不优于标准抗血小板治疗策略。

而最新分析显示,在复杂PCI术后患者中,长期单用替格瑞洛策略组患者的主要复合终点事件风险降低了36%,死亡和新发Q波心肌梗死发生风险分别降低了33%和47%。

而且,随着患者的高危特征增多,长期单用替格瑞洛策略的益处更大。

研究者指出,主分析中1年时两种抗血小板治疗策略在主要终点事件上是有显着差别的,2年时之所有差别不再明显,可能与长期单用替格瑞洛的患者依从性较低(78%)而标准抗血小板治疗策略组依从性高达93%有关。

复杂PCI定义为:弥漫性多支病变、至少置入3枚支架、至少治疗3处病变、分叉病变至少置入两枚支架、支架总长度超过60 mm。

在该研究中,复杂PCI组4570例,非复杂PCI组11 880例。复杂PCI组患者的缺血和出血事件风险均较高。

2年时,复杂PCI组中长期单用替格瑞洛的患者发生不良事件(全因死亡、中风、心肌梗死、血运重建)的风险降低了20%,但在非复杂PCI组没有降低。

两种抗血小板治疗策略下,BARC 3型或5型出血风险相似。在复杂PCI组中,长期单用替格瑞洛的患者净不良临床事件(上述事件+BARC 3型或5型出血)发生风险较低。

不过,GLOBAL LEADERS研究者之一Peter Jüni在讨论时指出,这项最新分析结果并非预先设定,且基于一项阴性试验得出,因此还需要更多数据来复制、验证。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1815110, encodeId=159a181511023, content=<a href='/topic/show?id=f61996989be' target=_blank style='color:#2F92EE;'>#长期单用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96989, encryptionId=f61996989be, topicName=长期单用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Mon Apr 13 11:15:00 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009535, encodeId=e479200953572, content=<a href='/topic/show?id=4f133e56590' target=_blank style='color:#2F92EE;'>#双联抗血小板#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37565, encryptionId=4f133e56590, topicName=双联抗血小板)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Thu Jun 06 19:15:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515607, encodeId=e01a151560ed0, content=<a href='/topic/show?id=59ab3e5660f' target=_blank style='color:#2F92EE;'>#双联抗血小板治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37566, encryptionId=59ab3e5660f, topicName=双联抗血小板治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9010842042, createdName=12498bf3m28暂无昵称, createdTime=Sun Jun 02 10:15:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585877, encodeId=610215858e78f, content=<a href='/topic/show?id=e2153094200' target=_blank style='color:#2F92EE;'>#冠脉介入术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30942, encryptionId=e2153094200, topicName=冠脉介入术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfd017309376, createdName=jklm15, createdTime=Sun Jun 02 10:15:00 CST 2019, time=2019-06-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1815110, encodeId=159a181511023, content=<a href='/topic/show?id=f61996989be' target=_blank style='color:#2F92EE;'>#长期单用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96989, encryptionId=f61996989be, topicName=长期单用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Mon Apr 13 11:15:00 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009535, encodeId=e479200953572, content=<a href='/topic/show?id=4f133e56590' target=_blank style='color:#2F92EE;'>#双联抗血小板#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37565, encryptionId=4f133e56590, topicName=双联抗血小板)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Thu Jun 06 19:15:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515607, encodeId=e01a151560ed0, content=<a href='/topic/show?id=59ab3e5660f' target=_blank style='color:#2F92EE;'>#双联抗血小板治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37566, encryptionId=59ab3e5660f, topicName=双联抗血小板治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9010842042, createdName=12498bf3m28暂无昵称, createdTime=Sun Jun 02 10:15:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585877, encodeId=610215858e78f, content=<a href='/topic/show?id=e2153094200' target=_blank style='color:#2F92EE;'>#冠脉介入术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30942, encryptionId=e2153094200, topicName=冠脉介入术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfd017309376, createdName=jklm15, createdTime=Sun Jun 02 10:15:00 CST 2019, time=2019-06-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1815110, encodeId=159a181511023, content=<a href='/topic/show?id=f61996989be' target=_blank style='color:#2F92EE;'>#长期单用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96989, encryptionId=f61996989be, topicName=长期单用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Mon Apr 13 11:15:00 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009535, encodeId=e479200953572, content=<a href='/topic/show?id=4f133e56590' target=_blank style='color:#2F92EE;'>#双联抗血小板#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37565, encryptionId=4f133e56590, topicName=双联抗血小板)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Thu Jun 06 19:15:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515607, encodeId=e01a151560ed0, content=<a href='/topic/show?id=59ab3e5660f' target=_blank style='color:#2F92EE;'>#双联抗血小板治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37566, encryptionId=59ab3e5660f, topicName=双联抗血小板治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9010842042, createdName=12498bf3m28暂无昵称, createdTime=Sun Jun 02 10:15:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585877, encodeId=610215858e78f, content=<a href='/topic/show?id=e2153094200' target=_blank style='color:#2F92EE;'>#冠脉介入术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30942, encryptionId=e2153094200, topicName=冠脉介入术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfd017309376, createdName=jklm15, createdTime=Sun Jun 02 10:15:00 CST 2019, time=2019-06-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1815110, encodeId=159a181511023, content=<a href='/topic/show?id=f61996989be' target=_blank style='color:#2F92EE;'>#长期单用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96989, encryptionId=f61996989be, topicName=长期单用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Mon Apr 13 11:15:00 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009535, encodeId=e479200953572, content=<a href='/topic/show?id=4f133e56590' target=_blank style='color:#2F92EE;'>#双联抗血小板#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37565, encryptionId=4f133e56590, topicName=双联抗血小板)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Thu Jun 06 19:15:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515607, encodeId=e01a151560ed0, content=<a href='/topic/show?id=59ab3e5660f' target=_blank style='color:#2F92EE;'>#双联抗血小板治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37566, encryptionId=59ab3e5660f, topicName=双联抗血小板治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9010842042, createdName=12498bf3m28暂无昵称, createdTime=Sun Jun 02 10:15:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585877, encodeId=610215858e78f, content=<a href='/topic/show?id=e2153094200' target=_blank style='color:#2F92EE;'>#冠脉介入术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30942, encryptionId=e2153094200, topicName=冠脉介入术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfd017309376, createdName=jklm15, createdTime=Sun Jun 02 10:15:00 CST 2019, time=2019-06-02, status=1, ipAttribution=)]

相关资讯

Chin Med J :韩雅玲院士团队发现:通心络可减少冠脉介入术后患者血小板高反应性

对于接受经皮冠脉介入治疗的急性冠脉综合征患者来说,术后氯吡格雷治疗期间如果出现血小板高反应性,意味着发生缺血事件的风险较高。

Chin Circul J:冠脉介入后运动康复3个月可改善心功能

冠心病患者置入支架后进行运动康复会有什么变化?内蒙古自治区鄂尔多斯中心医院冯玉宝、许艳梅等研究发现,对这类患者进行3个月的运动康复,其半年内心功能就明显改善,运动耐力和生活质量也上了个台阶。 研究显示,在冠脉介入治疗1个月时,参与运动康复者就比常规治疗者心功能恢复更为看好,其中尤以6 min 步行距离最为显著。 术后3、6个月时,不论是常规治疗还是运动康复,心功能各项指标均有明

Baidu
map
Baidu
map
Baidu
map